Know What's Happening in BioTech

DNA Origami Vaccine Rivals mRNA Shots While Being Easier to Store and Manufacture
NewsMar 11, 2026

DNA Origami Vaccine Rivals mRNA Shots While Being Easier to Store and Manufacture

Researchers at Harvard’s Wyss Institute and Dana‑Farber unveiled DoriVac, a DNA origami‑based vaccine platform that delivers antigens and adjuvants on a self‑folding nanostructure. In pre‑clinical mouse studies and a human lymph‑node‑on‑a‑chip model, DoriVac generated antibody and T‑cell responses comparable to...

By Phys.org – Nanotechnology
Researchers Use AI to Develop RNA-Based Synthetic NAND Switch in Living Cells
NewsMar 11, 2026

Researchers Use AI to Develop RNA-Based Synthetic NAND Switch in Living Cells

Researchers at TU Darmstadt have engineered the first RNA‑based synthetic NAND gate by linking two riboswitches that respond to distinct ligands. Using high‑throughput screening combined with a deep‑learning‑driven Bayesian optimization loop, they evaluated only 82 variants to isolate sequences that exhibit...

By Phys.org – Biotechnology
Startup Vima Adds Parkinson’s to Movement Disorder Scope, Expanding Series A Round to $100M
NewsMar 11, 2026

Startup Vima Adds Parkinson’s to Movement Disorder Scope, Expanding Series A Round to $100M

Vima Therapeutics announced an additional $40 million raise, taking its Series A funding to $100 million. The capital will support parallel Phase 2 trials of its lead candidate VIM0423 in isolated dystonia and Parkinson’s disease, expanding the startup’s focus beyond the rare movement disorder....

By MedCity News
Gut‑brain Signaling Fixes Age‑related Memory Loss
SocialMar 11, 2026

Gut‑brain Signaling Fixes Age‑related Memory Loss

Intestinal interoceptive dysfunction drives age-associated cognitive decline "We leverage this pathway to define interventions that enhance memory in aged mice, such as phage targeting of Parabacteroides, GPR84 inhibition and restoration of vagal activity. These findings indicate a key role for interoceptive dysfunction...

By David Barzilai, MD PhD
Can FDA Tolerate Cancer Risk for Rare Pediatric Disease Gene Therapies?
NewsMar 11, 2026

Can FDA Tolerate Cancer Risk for Rare Pediatric Disease Gene Therapies?

The FDA placed a clinical hold on Regenxbio’s RGX‑111 and RGX‑121 gene‑therapy trials after a pediatric MPS I patient developed a tumor four years post‑treatment. The case marks the first documented long‑latency cancer linked to an adeno‑associated virus (AAV) vector in...

By BioCentury
Science Spotlight: New Ways to Attack Β-Amyloid Plaques in Alzheimer’s
NewsMar 11, 2026

Science Spotlight: New Ways to Attack Β-Amyloid Plaques in Alzheimer’s

Two pre‑clinical studies propose active clearance of β‑amyloid as a new Alzheimer’s strategy. Researchers at Washington University engineered astrocytes with chimeric antigen receptors (CARs) that engulf plaques, while another team designed bispecific peptides that ferry amyloid into cells for lysosomal...

By BioCentury
Artificial Kinetochores Take the Pressure Off Aging Chromosomes During Meiosis
NewsMar 11, 2026

Artificial Kinetochores Take the Pressure Off Aging Chromosomes During Meiosis

Researchers at RIKEN have engineered protein‑based artificial kinetochores that compete with natural chromosome kinetochores for microtubule attachment during meiosis. By lowering the overall pulling force, these constructs keep weakened chromosome pairs together in aged mouse oocytes, restoring accurate DNA segregation....

By Phys.org – Biotechnology
Hawley Unveils Bill to Ban Abortion Pill, Strip FDA Approval
NewsMar 11, 2026

Hawley Unveils Bill to Ban Abortion Pill, Strip FDA Approval

Senator Josh Hawley introduced a bill to immediately withdraw the FDA's safety approval for mifepristone, the primary abortion medication. The legislation follows recent Supreme Court and Trump‑era reviews of the drug and cites a controversial conservative study alleging serious adverse...

By Courthouse News Service
AGENT IDE Midterm Results Still Give DCB an Edge for In-Stent Restenosis
NewsMar 11, 2026

AGENT IDE Midterm Results Still Give DCB an Edge for In-Stent Restenosis

Three‑year follow‑up of the AGENT IDE trial shows the Agent paclitaxel‑coated balloon (DCB) outperforms uncoated balloon angioplasty in treating in‑stent restenosis (ISR), with target‑lesion failure (TLF) rates of 32.7% versus 40.9% (hazard ratio 0.72). The advantage is driven mainly by...

By TCTMD
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
NewsMar 11, 2026

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Foghorn Therapeutics announced a financial update highlighting progress on its lead oncology candidate FHD-909, which remains on schedule in Phase 1 dose‑escalation for SMARCA4‑mutant NSCLC. The company also confirmed that its selective CBP and EP300 degrader programs are slated for...

By The Manila Times – Business
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
NewsMar 11, 2026

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Elutia Inc. reported its Q4 and full‑year 2025 results, highlighting the $88 million sale of its BioEnvelope business to Boston Scientific and a cash position of $36.4 million plus $8 million in escrow. The company submitted a 510(k) for the base biologic matrix...

By The Manila Times – Business
NanoTess Lands Embecta Deal to Put Its Tech in 14,000 Canadian Pharmacies
NewsMar 11, 2026

NanoTess Lands Embecta Deal to Put Its Tech in 14,000 Canadian Pharmacies

Calgary‑based NanoTess has signed a distribution agreement with diabetes‑care company Embecta to place its NanoSALV Catalytic gel in more than 14,000 Canadian pharmacies. NanoSALV, authorized by Health Canada in 2022, uses micron‑scale catalytic particles to speed cellular reactions, reduce inflammation...

By BetaKit (Canada)
FDA Merges Adverse Event Trackers Into One Database
NewsMar 11, 2026

FDA Merges Adverse Event Trackers Into One Database

The FDA announced a unified adverse‑event database that will eventually incorporate all of its existing reporting systems, including the vaccine‑side‑effect tracker jointly operated with the CDC. The new platform, called the Adverse Event Monitoring System, centralizes data from drugs, biologics,...

By Endpoints News
FDA Clears New Large-Bore Catheter for Challenging Stroke Cases
NewsMar 11, 2026

FDA Clears New Large-Bore Catheter for Challenging Stroke Cases

Toro Neurovascular has obtained FDA clearance for its Toro 88 Superbore Catheter, a large‑bore device engineered for challenging stroke interventions. The catheter promises enhanced support, trackability, and stability, addressing the time‑sensitive nature of neurovascular procedures. UCLA interventional neuroradiologist Dr. Satoshi Tateshima...

By Cardiovascular Business
Pharmaceutical Executive Daily: FDA's New Guidance for Biosimilar Development
BlogMar 11, 2026

Pharmaceutical Executive Daily: FDA's New Guidance for Biosimilar Development

The FDA issued its fourth revision of draft biosimilar development guidance, allowing scientifically justified streamlining of pharmacokinetic (PK) studies and estimating up to a 50% cost reduction—about $20 million per program. The new guidance also expands the use of clinical data...

By Pharmaceutical Executive (independent trade outlet)
Tailored Training Can Address Biopharma Skills Shortage
NewsMar 11, 2026

Tailored Training Can Address Biopharma Skills Shortage

Ireland’s National Institute for Bioprocess Research and Training (NIBRT) reports a persistent global shortage of biopharma manufacturing talent, especially engineers skilled in digital bioprocessing, automation and AI. The gap spans cell culture, downstream processing, aseptic manufacturing and quality functions, with...

By GEN (Genetic Engineering & Biotechnology News)
New Chromatography Resin Developed for Secretory Antibodies
NewsMar 11, 2026

New Chromatography Resin Developed for Secretory Antibodies

Researchers at BOKU University in Vienna have engineered a novel chromatography resin designed to capture secretory immunoglobulin A (IgA) at titers suitable for commercial manufacturing. The resin employs a reengineered bacterial surface ligand, analogous to Protein A, within a macropore...

By GEN (Genetic Engineering & Biotechnology News)
Giovanni Traverso
NewsMar 11, 2026

Giovanni Traverso

Giovanni Traverso, M.D., Ph.D., is a physician‑scientist who bridges gastroenterology and engineering as an associate member of the Broad Institute, director of the Laboratory for Translational Engineering, MIT associate professor, and Harvard gastroenterologist. His lab creates ingestible electronics, robotic capsules,...

By Broad Institute News
A Better View of How Cells Take Up Mitochondria to Restore Function
BlogMar 11, 2026

A Better View of How Cells Take Up Mitochondria to Restore Function

Researchers have demonstrated that mesenchymal stromal cells (MSCs) can actively internalize isolated, functional mitochondria through endocytic pathways. The study shows that the internalized organelles retain structural integrity and boost cellular proliferation, stress tolerance, and oxygen consumption. Chemical inhibition of endocytosis...

By Fight Aging!
Trouble Swallowing? A Nanogel Tweak May Keep Therapeutic Stem Cells Alive Longer
NewsMar 11, 2026

Trouble Swallowing? A Nanogel Tweak May Keep Therapeutic Stem Cells Alive Longer

Researchers at Kyoto University and McGill University created hybrid stem‑cell spheroids incorporating biodegradable nanogel microfibers. The nanogel‑enhanced spheroids improved oxygen diffusion, increasing cell viability more than fivefold and boosting secretion of regenerative factors. In a rat model of swallowing‑muscle injury,...

By Phys.org – Nanotechnology
Safer Large DNA Insertion Moves Genetic Medicine Toward Scalability
NewsMar 11, 2026

Safer Large DNA Insertion Moves Genetic Medicine Toward Scalability

Researchers at Massachusetts General Hospital, in partnership with Full Circles Therapeutics, have introduced a circular single‑stranded DNA donor platform called INSTALL that enables kilobase‑scale gene insertion without triggering the cGAS immune sensor. The method combines a short double‑stranded DNA segment...

By GEN (Genetic Engineering & Biotechnology News)
Simple 'Cocktail' Of Amino Acids Dramatically Boosts Power of mRNA Therapies and CRISPR Gene Editing
NewsMar 11, 2026

Simple 'Cocktail' Of Amino Acids Dramatically Boosts Power of mRNA Therapies and CRISPR Gene Editing

Researchers at Biohub identified a three‑amino‑acid cocktail—methionine, arginine and serine—that dramatically improves lipid nanoparticle (LNP) delivery of therapeutic mRNA and CRISPR components. Co‑administering the supplement boosted protein expression up to 20‑fold and raised gene‑editing rates from roughly 25% to nearly...

By Phys.org – Nanotechnology
Biodegradable Nanoparticles Can Seek and Destroy Diseased Immune Cells
NewsMar 11, 2026

Biodegradable Nanoparticles Can Seek and Destroy Diseased Immune Cells

Johns Hopkins researchers have engineered a streamlined biodegradable polymeric nanoparticle that delivers mRNA to T cells, prompting them to generate CD19‑CAR receptors that target disease‑causing B cells. In mice, a single intravenous dose eliminated 95% of circulating B cells within...

By Phys.org – Nanotechnology
A New AI Model Could Help Scientists Design New Forms of Life
NewsMar 11, 2026

A New AI Model Could Help Scientists Design New Forms of Life

Researchers at the Arc Institute unveiled Evo2, an AI model trained on trillions of DNA bases from diverse organisms. By treating DNA as language, Evo2 can generate genome‑scale sequences millions of letters long, demonstrated with Mycoplasma genitalium‑inspired designs. The model...

By EnterpriseAI
VIDO – Six Years Later: How VIDO Helped Respond to the COVID-19 Pandemic
NewsMar 11, 2026

VIDO – Six Years Later: How VIDO Helped Respond to the COVID-19 Pandemic

VIDO swiftly responded to COVID‑19 by designing a subunit vaccine candidate within days of the SARS‑CoV‑2 genome release, isolating the virus, and establishing animal models that enabled a Phase 1 human trial by early 2021, making it the first Canadian university...

By BIOTECanada
The Gut Microbiome May Influence Brain Aging, Mouse Study Suggests
NewsMar 11, 2026

The Gut Microbiome May Influence Brain Aging, Mouse Study Suggests

A University of Pennsylvania study published in Nature shows that gut bacteria from aged mice can impair memory in young mice, effectively accelerating brain aging. The researchers identified the bacterium *Parabacteroides goldsteinii* as the key agent, linking it to inflammation...

By Scientific American – Mind
Endometriosis Study Aims for Safer Diagnosis
NewsMar 11, 2026

Endometriosis Study Aims for Safer Diagnosis

A Worcestershire Acute NHS Trust‑led clinical trial is testing a non‑invasive electrode‑based method to diagnose endometriosis, marking the first such study within the NHS. The technique records small‑intestine muscle activity, which researchers claim shows a pattern unique to patients with...

By BBC News – Health
Engineering Meat: Science Drives Next Agricultural Revolution
SocialMar 11, 2026

Engineering Meat: Science Drives Next Agricultural Revolution

For 12,000 years, humanity has produced meat the same way: grow crops, feed animals, convert plants into protein. From a biomanufacturing perspective, it is one of the most complex and least optimized production systems on the planet. What happens when we start...

By John Cumbers
Phase 2 Trial Compares Dara‑Bor
SocialMar 11, 2026

Phase 2 Trial Compares Dara‑Bor

EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/IvK3UNeem9

By Mike Thompson, MD PhD
From Insights to Impact: Rare Disease Therapies with UCB’s Dr. Kim Moran — Episode 246
BlogMar 11, 2026

From Insights to Impact: Rare Disease Therapies with UCB’s Dr. Kim Moran — Episode 246

UCB’s Senior Vice President Dr. Kim Moran discusses the company’s rare disease pipeline, including therapies for mitochondrial TK2 deficiency, on Xtalks Life Science Podcast episode 246. Moran, who pioneered UCB’s Insights‑to‑Impact function, explains how patient‑derived data informs strategy, digital transformation,...

By Xtalks – Biotech Blogs
Phase 3
SocialMar 11, 2026

Phase 3

#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMx3J8 #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd https://t.co/FLK0sJ0N1w

By Mike Thompson, MD PhD
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
SocialMar 11, 2026

Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/ikQKjHjscU

By Mike Thompson, MD PhD
Biogen Phase Ib Data Positions Salanersen for SMA Treatment Sequencing
NewsMar 11, 2026

Biogen Phase Ib Data Positions Salanersen for SMA Treatment Sequencing

Biogen reported Phase Ib data for its antisense oligonucleotide salanersen, showing substantial neurofilament light chain reductions and new motor milestones in children with spinal muscular atrophy (SMA) who had previously received onasemnogene abeparvovec. The study of 24 participants demonstrated a roughly...

By BioPharm International
Phase 3 Trial Tests
SocialMar 11, 2026

Phase 3 Trial Tests

.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/FoT3i0xGcL

By Mike Thompson, MD PhD
Mapping Genomic Alterations in Multiple Myeloma Precursors
SocialMar 11, 2026

Mapping Genomic Alterations in Multiple Myeloma Precursors

Genomic landscape of multiple myeloma and its precursor conditions [May 21, 2025] Jean-Baptiste Alberge et al. @IrenemGhobrial @NatureGenet https://t.co/DDWGRrpI4Y #mmsm #PrecisionMedicine #cagenome https://t.co/LY1MzFXSBN

By Mike Thompson, MD PhD
Lonza Expands Agreement to Manufacture Gene Therapy for Transfusion-Dependent Beta-Thalassemia
NewsMar 11, 2026

Lonza Expands Agreement to Manufacture Gene Therapy for Transfusion-Dependent Beta-Thalassemia

Lonza has broadened its agreement with Genetix Biotherapeutics to increase manufacturing capacity for ZYNTEGLO, the sole FDA‑approved gene therapy for transfusion‑dependent beta‑thalassemia. Production will continue at Lonza’s Houston, Texas, dedicated cell‑and‑gene therapy site, with provisions to scale up for future...

By GEN (Genetic Engineering & Biotechnology News)
Multiple Myeloma Evades GPRC5D T‑Cell Engagers via Multim
SocialMar 11, 2026

Multiple Myeloma Evades GPRC5D T‑Cell Engagers via Multim

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma [Jan 15, 2026] @hollyleeYJ et al. @NBahlis @NatureMedicine https://t.co/mz393mPMAq #mmsm #PrecisionMedicine #tcellrx THREAD: https://t.co/lNX9b7LsnR HT @AuclairDan https://t.co/2qih7LwP1c

By Mike Thompson, MD PhD
First In‑Utero Stem Cell Surgery Cures Spina Bifida
SocialMar 11, 2026

First In‑Utero Stem Cell Surgery Cures Spina Bifida

In a First, Researchers Use Stem Cells and Surgery to Treat Spina Bifida in the Womb by @ShellyFan https://t.co/4xO4I0iLJL https://t.co/HV1CGzlMXU

By Brian Ahier
Seven Ways to Skin KRAS: Emerging Approaches to Watch Out For
BlogMar 11, 2026

Seven Ways to Skin KRAS: Emerging Approaches to Watch Out For

The article surveys seven early‑stage programmes tackling KRAS, each proposing a distinct therapeutic angle. While many firms still chase the classic model of deeper, longer, or more selective pathway blockade, these initiatives span elegant biochemical tricks to counterintuitive concepts that...

By Biotech Strategy Blog
Sequencing Hematologic Cancers Reveals Germline Variant Candidates
SocialMar 11, 2026

Sequencing Hematologic Cancers Reveals Germline Variant Candidates

Identifying potential germline variants from sequencing hematopoietic malignancies [Dec 4, 2020] Ira L. Kraft, Lucy A. Godley @ASH_hematology Education Book https://t.co/L09eJ55sNW #geneticcounselors #PrecisionMedicine #hemeonc https://t.co/Ggq8IEzQEa

By Mike Thompson, MD PhD
Regulation Will Push Peptide Market to Clean Providers
SocialMar 11, 2026

Regulation Will Push Peptide Market to Clean Providers

Consider this arc: peptides were around in niche communities, GLPs from Pharma then exploded, people realized they could take less or source them elsewhere, regulation enters & now gray & black market are going bye-bye & companies like HIMs &...

By Andrew Huberman – Huberman Lab
The FDA Approves Leucovorin for Rare Genetic Condition and Not for Autism
NewsMar 11, 2026

The FDA Approves Leucovorin for Rare Genetic Condition and Not for Autism

The U.S. Food and Drug Administration approved leucovorin, a synthetic vitamin B9, solely for cerebral folate deficiency, a rare genetic disorder. Earlier this year, President Trump and HHS Secretary Robert Kennedy Jr. promoted the drug as an autism cure, prompting a surge in...

By Scientific American – Mind
Day 3 Tackles Extending Healthspan and Achieving Longevity Escape Velocity
SocialMar 11, 2026

Day 3 Tackles Extending Healthspan and Achieving Longevity Escape Velocity

The @abundance360 Day 3 is at full force, covering one of the most important topics for humanity: how do we extend human healthspan & achieve LEV. We have a powerful lineup of speakers, including my friend @davidasinclair ! https://t.co/SLfeDlbo5f

By Peter H. Diamandis
Black Stripe Marks Successful Agroinfiltration, Red
SocialMar 11, 2026

Black Stripe Marks Successful Agroinfiltration, Red

More agroinfiltration tests. Black sharpie stripe indicates injecred bloom. Right lobe is positive control. Should turn red in the next 72hrs. https://t.co/2lRTbwAjhq

By Sebastian Cocioba
Inside The Race To Reboot Human Cells - EP 60 Nabiha Saklayen
PodcastMar 11, 20260 min

Inside The Race To Reboot Human Cells - EP 60 Nabiha Saklayen

In this episode, host Ashley Vance talks with Nabiha Saklayen, co‑founder and CEO of Celino, about induced pluripotent stem cells (iPSCs) and their rapid evolution from a Nobel‑winning discovery to emerging therapies. They discuss how iPSCs can be reprogrammed from...

By Core Memory
Emerging KRAS Combo Therapies Show Promising Progress
SocialMar 11, 2026

Emerging KRAS Combo Therapies Show Promising Progress

The KRAS niche has been a deluge of new selective and pan/multi inhibitors. Now there are combos to watch out for – we may be making progress. Here are insights on 7 of them: https://t.co/F9HmM8A4ud https://t.co/IqWw6n2m3k

By Sally Church
GLP‑1 Drug Linked to Longer Survival in Brain Metastases
SocialMar 11, 2026

GLP‑1 Drug Linked to Longer Survival in Brain Metastases

Another potential GLP-1 drug benefit seen in people with diabetes and brain metastases for improved survival; a retrospective study that needs further assessment but intriguing https://t.co/nZm3xEYQMH https://t.co/V76S7o1MJb

By Eric Topol
Alzheimer’s Blood Markers Also Flag Certain Amyloidosis Types
SocialMar 11, 2026

Alzheimer’s Blood Markers Also Flag Certain Amyloidosis Types

The blood neuromarkers p-tau181 and p-tau217 that can predict and diagnose Alzheimer's disease are also abnormal in certain types of amyloidosis, indicating both some non-specificity and potential help in diagnosis of these conditions https://t.co/jodvMY6TNK

By Eric Topol
Severe COVID/Flu May Boost Lung Cancer Risk
SocialMar 11, 2026

Severe COVID/Flu May Boost Lung Cancer Risk

A causal link between severe Covid or flu and lung cancer risk by impairing immunity and promoting inflammation, as shown in multiple murine models https://t.co/NvE6uIYFZh

By Eric Topol